首页 > 最新文献

Indian heart journal最新文献

英文 中文
Establishing Apolipoprotein-B and non-high-density-lipoprotein-C goals in Indian population: A Cross-sectional study 确定印度人口载脂蛋白-B 和非高密度脂蛋白-C 的目标:一项横断面研究。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.003

Background

Defining lipid goals solely on low-density lipoprotein-cholesterol (LDL-C) levels in Indian population may cause misclassification due to high prevalence of hypertriglyceridemia and small dense LDL-C particles. International guidelines now recommend Apoliporotein-B (Apo-B) and non-high-density lipoprotein-cholesterol (non-HDL-C) levels as alternative targets. In this study, we used a cross-sectional representative population database to determine Apo-B and non-HDL-C cut-offs corresponding to identified LDL-C targets and compared them to international guidelines.

Methods

A community-based survey carried out in urban Delhi and adjacent rural Ballabhgarh provided lipid values for 3047 individuals. The Spearman correlation coefficient was used to evaluate the degree of relationship between Apo-B and LDL-C and non-HDL-C. Cut-off values for Apo-B and non-HDL-C were established using receiver operator curve analysis correlating with guideline-recommended LDL-C targets.

Results

Spearman's rank correlations between Apo-B and LDL-C (0.82) and non-HDL-C and LDL-C (0.93) were significant (p < 0.05). Proposed corresponding cut-off values for LDL-C of 55, 70,100,130 and 160 mg/dl for Apo-B and non-HDL-C in our population were 75.3, 75.5, 91.3, 107.6, 119.4 mg/dL and 92.5,96.5, 123.5, 154.5, 179.5 mg/dL respectively. However, in those with triglycerides >150 mg/dl the corresponding Apo-B and non-HDL-C values were 85.1, 92.7, 103.5, 117.5 and 135 mg/dL and 124.5, 126.5, 147.5, 167.5 and 190.5 mg/L respectively.

Conclusion

Based on this study we provide Apo-B and non-HDL cut-offs corresponding to target LDL-C values in Indian patients with and without high triglycerides. It is noted that in individuals with triglycerides ≥ 150 mg/dl, the Apo-B levels are much higher than the values recommended by guidelines.

背景:在印度人群中,由于高甘油三酯血症和低密度脂蛋白胆固醇小颗粒的发病率较高,仅根据低密度脂蛋白胆固醇(LDL-C)水平来确定血脂目标可能会造成分类错误。目前,国际指南推荐将载脂蛋白-B(Apo-B)和非高密度脂蛋白胆固醇(non-HDL-C)水平作为替代目标。在这项研究中,我们利用一个具有代表性的横断面人口数据库,确定了与已确定的低密度脂蛋白胆固醇目标相对应的载脂蛋白-B和非高密度脂蛋白胆固醇临界值,并将其与国际指南进行了比较:在德里市区和邻近的巴拉布格尔农村地区开展的一项社区调查提供了 3047 人的血脂值。采用斯皮尔曼相关系数评估载脂蛋白-B 与低密度脂蛋白胆固醇和非高密度脂蛋白胆固醇之间的关系程度。利用接收器运算曲线分析法确定了载脂蛋白-B 和非高密度脂蛋白胆固醇的临界值,并与指南推荐的低密度脂蛋白胆固醇目标值相关联:结果:载脂蛋白-B 和低密度脂蛋白胆固醇(0.82)以及非高密度脂蛋白胆固醇和低密度脂蛋白胆固醇(0.93)之间的斯皮尔曼等级相关性显著(p 150 mg/dl,相应的载脂蛋白-B 和非高密度脂蛋白胆固醇值分别为 85.1、92.7、103.5、117.5 和 135 mg/dL 以及 124.5、126.5、147.5、167.5 和 190.5 mg/L:根据这项研究,我们提供了与甘油三酯高和甘油三酯不高的印度患者的 LDL-C 目标值相对应的载脂蛋白-B 和非高密度脂蛋白临界值。我们注意到,在甘油三酯>= 150mg/dl 的人群中,载脂蛋白-B 水平远高于指南推荐值。
{"title":"Establishing Apolipoprotein-B and non-high-density-lipoprotein-C goals in Indian population: A Cross-sectional study","authors":"","doi":"10.1016/j.ihj.2024.06.003","DOIUrl":"10.1016/j.ihj.2024.06.003","url":null,"abstract":"<div><h3>Background</h3><p>Defining lipid goals solely on low-density lipoprotein-cholesterol (LDL-C) levels in Indian population may cause misclassification due to high prevalence of hypertriglyceridemia and small dense LDL-C particles. International guidelines now recommend Apoliporotein-B (Apo-B) and non-high-density lipoprotein-cholesterol (non-HDL-C) levels as alternative targets. In this study, we used a cross-sectional representative population database to determine Apo-B and non-HDL-C cut-offs corresponding to identified LDL-C targets and compared them to international guidelines.</p></div><div><h3>Methods</h3><p>A community-based survey carried out in urban Delhi and adjacent rural Ballabhgarh provided lipid values for 3047 individuals. The Spearman correlation coefficient was used to evaluate the degree of relationship between Apo-B and LDL-C and non-HDL-C. Cut-off values for Apo-B and non-HDL-C were established using receiver operator curve analysis correlating with guideline-recommended LDL-C targets.</p></div><div><h3>Results</h3><p>Spearman's rank correlations between Apo-B and LDL-C (0.82) and non-HDL-C and LDL-C (0.93) were significant (p &lt; 0.05). Proposed corresponding cut-off values for LDL-C of 55, 70,100,130 and 160 mg/dl for Apo-B and non-HDL-C in our population were 75.3, 75.5, 91.3, 107.6, 119.4 mg/dL and 92.5,96.5<u>,</u> 123.5, 154.5, 179.5 mg/dL respectively. However, in those with triglycerides &gt;150 mg/dl the corresponding Apo-B and non-HDL-C values were 85.1, 92.7, 103.5, 117.5 and 135 mg/dL and 124.5, 126.5, 147.5, 167.5 and 190.5 mg/L respectively.</p></div><div><h3>Conclusion</h3><p>Based on this study we provide Apo-B and non-HDL cut-offs corresponding to target LDL-C values in Indian patients with and without high triglycerides. It is noted that in individuals with triglycerides ≥ 150 mg/dl, the Apo-B levels are much higher than the values recommended by guidelines.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 154-158"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000762/pdfft?md5=da3b7deb63392bc340d436d3d13ffeb3&pid=1-s2.0-S0019483224000762-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AST/ALT Ratio as an indicator of functional severity in chronic heart failure with reduced left ventricular ejection fraction: A prospective cross-sectional study AST/ALT 比率作为左心室射血分数降低的慢性心力衰竭患者功能严重程度的指标:一项前瞻性横断面研究
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.004

Objective

The study was carried out to evaluate the role of the AST (Aspartate transaminase)/ALT (Alanine transaminase) ratio as an indicator of the functional severity in people with chronic heart failure (CHF) with reduced left ventricular ejection fraction.

Methods

A prospective cross-sectional study was conducted in a tertiary care centre in South India among the individuals who had left ventricular ejection fraction (LVEF) of ≤40 %. The study period was between January 2021 and December 2021. Consecutive patients with the criteria were enrolled in the study. Study participants were grouped based on their AST/ALT ratio value (ratio<1 and ratio≥1).

Results

In present study of 100 participants, there was a statistically significant difference between two groups with respect to ALT, AST/ALT ratio, and ALP (Alkaline phosphatase). There was a significant correlation between the APRI (AST to platelet ratio index) and FIB-4 (Fibrosis-4) with AST/ALT ratio. Diagnostic analysis of AST/ALT ratio to predict the severity of CHF with reduced EF, the area under the curve (AUC) was 0.547 (p-value = 0.5654) with a 95 % confidence interval of 0.299–0.795 with an optimal cut-off value of 0.6, sensitivity of 96.70 %, and specificity of 33.33 %.

Conclusion

The AST/ALT ratio is increased in patients with CHF patients with reduced left ventricular ejection fraction. It is a simple predictor of left ventricular dysfunction in patients with heart failure with reduced ejection fraction.

研究目的本研究旨在评估天冬氨酸转氨酶/丙氨酸转氨酶比值作为左心室射血分数降低的慢性心力衰竭(CHF)患者功能严重程度指标的作用:在印度南部的一家三级医疗中心对左心室射血分数(LVEF)≤40%的患者进行了一项前瞻性横断面研究。研究时间为 2021 年 1 月至 2021 年 12 月。符合标准的连续患者被纳入研究。研究参与者根据其谷草转氨酶/谷丙转氨酶比值(ratioResults:在对 100 名参与者进行的这项研究中,两组之间在谷丙转氨酶、谷草转氨酶/谷丙转氨酶比值和碱性磷酸酶(ALP)方面存在显著的统计学差异。APRI(谷草转氨酶与血小板比率指数)和 FIB-4(纤维化-4)与谷草转氨酶/谷丙转氨酶比率之间存在明显的相关性。用 AST/ALT 比值预测 EF 值降低的 CHF 严重程度的诊断分析结果显示,曲线下面积(AUC)为 0.547(P 值 = 0.5654),95% 置信区间为 0.299-0.795,最佳临界值为 0.6,敏感性为 96.70%,特异性为 33.33%:结论:左心室射血分数降低的慢性阻塞性肺疾病患者的 AST/ALT 比值会升高。结论:AST/ALT 比值在左心室射血分数降低的心力衰竭患者中会升高,是预测射血分数降低的心力衰竭患者左心室功能障碍的简单指标。
{"title":"AST/ALT Ratio as an indicator of functional severity in chronic heart failure with reduced left ventricular ejection fraction: A prospective cross-sectional study","authors":"","doi":"10.1016/j.ihj.2024.06.004","DOIUrl":"10.1016/j.ihj.2024.06.004","url":null,"abstract":"<div><h3>Objective</h3><p>The study was carried out to evaluate the role of the AST (Aspartate transaminase)/ALT (Alanine transaminase) ratio as an indicator of the functional severity in people with chronic heart failure (CHF) with reduced left ventricular ejection fraction.</p></div><div><h3>Methods</h3><p>A prospective cross-sectional study was conducted in a tertiary care centre in South India among the individuals who had left ventricular ejection fraction (LVEF) of ≤40 %. The study period was between January 2021 and December 2021. Consecutive patients with the criteria were enrolled in the study. Study participants were grouped based on their AST/ALT ratio value (ratio&lt;1 and ratio≥1).</p></div><div><h3>Results</h3><p>In present study of 100 participants, there was a statistically significant difference between two groups with respect to ALT, AST/ALT ratio, and ALP (Alkaline phosphatase). There was a significant correlation between the APRI (AST to platelet ratio index) and FIB-4 (Fibrosis-4) with AST/ALT ratio. Diagnostic analysis of AST/ALT ratio to predict the severity of CHF with reduced EF, the area under the curve (AUC) was 0.547 (<em>p</em>-value = 0.5654) with a 95 % confidence interval of 0.299–0.795 with an optimal cut-off value of 0.6, sensitivity of 96.70 %, and specificity of 33.33 %.</p></div><div><h3>Conclusion</h3><p>The AST/ALT ratio is increased in patients with CHF patients with reduced left ventricular ejection fraction. It is a simple predictor of left ventricular dysfunction in patients with heart failure with reduced ejection fraction.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 202-206"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000774/pdfft?md5=17d2ca99dbfd39a9508fa714dd290820&pid=1-s2.0-S0019483224000774-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgery compared to fibrinolytic therapy for symptomatic left-sided prosthetic heart valve thrombosis (SAFE-PVT): Rationale and design of a randomized controlled trial 手术与纤维蛋白溶解疗法治疗症状性左侧人工心脏瓣膜血栓形成(SAFE-PVT)的比较:随机对照试验的原理与设计。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.013

Background

Left-sided mechanical prosthetic heart valve thrombosis (PVT) occurs because of suboptimal anticoagulation and is common in low-resource settings. Urgent surgery and fibrinolytic therapy (FT) are the two treatment options available for this condition. Urgent surgery is a high-risk procedure but results in successful restoration of valve function more often and is the treatment of choice in developed countries. In low-resource countries, FT is used as the default treatment strategy, though it is associated with lower success rates and a higher rate of bleeding and embolic complications. There are no randomized trials comparing the two modalities.

Methods

We performed a single center randomized controlled trial comparing urgent surgery (valve replacement or thrombectomy) with FT (low-dose, slow infusion tissue plasminogen activator, tPA) in patients with symptomatic left-sided PVT. The primary outcome was the occurrence of a complete clinical response, defined as discharge from hospital with completely restored valve function, in the absence of stroke, major bleeding or non-CNS systemic embolism. Outcome assessment was done by investigators blinded to treatment allocation. The principal safety outcome was the occurrence of a composite of in-hospital death, non-fatal stroke, non-fatal major bleed or non-CNS systemic embolism. Outcomes will be assessed both in the intention-to-treat, and in the as-treated population. We will also report outcomes at one year of follow-up. The trial has completed recruitment.

Conclusion

This is the first randomized trial to compare urgent surgery with FT for the treatment of left-sided PVT. The results will provide evidence to help clinicians make treatment choices for these patients.

(Clinical trial registration: CTRI/2017/10/010159).

背景:左侧机械人工心脏瓣膜血栓(PVT)的发生是由于抗凝效果不佳,在资源匮乏的环境中很常见。紧急手术和纤维蛋白溶解疗法(FT)是治疗这种疾病的两种方法。紧急手术是一种高风险手术,但通常能成功恢复瓣膜功能,是发达国家的首选治疗方法。在资源匮乏的国家,FT 是默认的治疗策略,但其成功率较低,出血和栓塞并发症发生率较高。目前还没有比较这两种方法的随机试验:我们进行了一项单中心随机对照试验,对有症状的左侧 PVT 患者进行了紧急手术(瓣膜置换术或血栓切除术)与 FT(低剂量、缓慢输注组织纤溶酶原激活剂 tPA)的比较。主要结果是出现完全临床反应,即出院时瓣膜功能完全恢复,且未发生中风、大出血或非中枢神经系统性栓塞。结果评估由治疗分配盲法研究人员进行。主要安全性结果是发生院内死亡、非致命性中风、非致命性大出血或非中枢神经系统性栓塞的复合情况。结果将在意向治疗和治疗人群中进行评估。我们还将报告随访一年的结果。该试验已完成招募:这是第一项比较紧急手术和 FT 治疗左侧脉搏搏动不全的随机试验。试验结果将为临床医生为这些患者做出治疗选择提供证据。(临床试验注册:CTRI/2017/10/010159)。
{"title":"Surgery compared to fibrinolytic therapy for symptomatic left-sided prosthetic heart valve thrombosis (SAFE-PVT): Rationale and design of a randomized controlled trial","authors":"","doi":"10.1016/j.ihj.2024.06.013","DOIUrl":"10.1016/j.ihj.2024.06.013","url":null,"abstract":"<div><h3>Background</h3><p>Left-sided mechanical prosthetic heart valve thrombosis (PVT) occurs because of suboptimal anticoagulation and is common in low-resource settings. Urgent surgery and fibrinolytic therapy (FT) are the two treatment options available for this condition. Urgent surgery is a high-risk procedure but results in successful restoration of valve function more often and is the treatment of choice in developed countries. In low-resource countries, FT is used as the default treatment strategy, though it is associated with lower success rates and a higher rate of bleeding and embolic complications. There are no randomized trials comparing the two modalities.</p></div><div><h3>Methods</h3><p>We performed a single center randomized controlled trial comparing urgent surgery (valve replacement or thrombectomy) with FT (low-dose, slow infusion tissue plasminogen activator, tPA) in patients with symptomatic left-sided PVT. The primary outcome was the occurrence of a complete clinical response, defined as discharge from hospital with completely restored valve function, in the absence of stroke, major bleeding or non-CNS systemic embolism. Outcome assessment was done by investigators blinded to treatment allocation. The principal safety outcome was the occurrence of a composite of in-hospital death, non-fatal stroke, non-fatal major bleed or non-CNS systemic embolism. Outcomes will be assessed both in the intention-to-treat, and in the as-treated population. We will also report outcomes at one year of follow-up. The trial has completed recruitment.</p></div><div><h3>Conclusion</h3><p>This is the first randomized trial to compare urgent surgery with FT for the treatment of left-sided PVT. The results will provide evidence to help clinicians make treatment choices for these patients.</p><p>(Clinical trial registration: CTRI/2017/10/010159).</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 192-196"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000865/pdfft?md5=57fef7783bce93dd6faed9ff89800159&pid=1-s2.0-S0019483224000865-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibrinolysis and clinical outcomes in acute pulmonary embolism. Madras medical college pulmonary embolism (M-PER) registry from India 急性肺栓塞的纤维蛋白溶解和临床结果。印度马德拉斯医学院肺栓塞(M-PER)登记。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.008

Background

Acute pulmonary embolism (APE) is the third most common cause of vascular death. Data on APE from India and other low-and middle-income countries is sparse.

Objectives

Study the clinical characteristics, prognostic factors, in-hospital mortality (IMH) and 12 months mortality of patients with APE in India.

Methods

We prospectively enrolled 186 consecutive patients diagnosed with APE between November 2016 and November 2021 in Madras Medical College Pulmonary Embolism Registry (M-PER). All patients had electrocardiography and echocardiography. High risk patients and selected intermediate risk patients underwent fibrinolysis.

Results

75 % of our patients were below 50 years of age. 35 % were women. The mean time to presentation from symptom onset was 6.04 ± 10.01 days. 92 % had CT pulmonary angiography. Intermediate risk category (61.3 %) was the more common presentation followed by high risk (26.9 %). Electrocardiography showed S1Q3T3 pattern in 56 %. 76 % had right ventricular dysfunction and 12.4 % had right heart thrombi(RHT) by echocardiography. 50.5 % received fibrinolysis. Patients with RHT received fibrinolysis more frequently (78.3 % vs 46.6 %; p = 0.007). In-hospital mortality (IHM) was 15.6 %. Systemic arterial desaturation and need for mechanical ventilation independently predicted IHM. Ten patients (5.3 %) were lost to follow up. One year mortality was 26.7 % (47/176). One year mortality of patients discharged alive was similar among high, intermediate and low risk groups(14.8 % vs 1.9 % vs 10.5 %; p = 0.891).

Conclusions

Patients with PE are often young and present late in India. The in-hospital and 12 months mortality were high. Low and intermediate risk groups had a high post discharge mortality similar to high risk patients.

背景:急性肺栓塞(APE)是血管性死亡的第三大常见原因。印度和其他中低收入国家关于急性肺栓塞的数据很少:研究印度 APE 患者的临床特征、预后因素、院内死亡率(IMH)和 12 个月死亡率:我们在马德拉斯医学院肺栓塞登记处(M-PER)前瞻性地登记了 2016 年 11 月至 2021 年 11 月期间确诊为 APE 的 186 例连续患者。所有患者均进行了心电图和超声心动图检查。高危患者和部分中危患者接受了纤维蛋白溶解术:75%的患者年龄在50岁以下。女性占 35%。从症状出现到就诊的平均时间为 6.04 ± 10.01 天。92% 的患者接受了 CT 肺血管造影检查。中危(61.3%)是最常见的表现,其次是高危(26.9%)。56%的患者心电图显示为S1Q3T3型。超声心动图显示,76%的患者存在右心室功能障碍,12.4%的患者存在右心血栓(RHT)。50.5%的患者接受了纤维蛋白溶解治疗。RHT患者接受纤维蛋白溶解的比例更高(78.3% vs 46.6%;P = 0.007)。院内死亡率 (IHM) 为 15.6%。全身动脉饱和度降低和需要机械通气可独立预测院内死亡率。10名患者(5.3%)失去了随访机会。一年死亡率为 26.7%(47/176)。高危、中危和低危组患者出院后一年的死亡率相似(14.8% vs 1.9% vs 10.5%;P = 0.891):印度的 PE 患者通常比较年轻,发病时间较晚。结论:印度的 PE 患者多为年轻人,发病时间较晚,院内死亡率和 12 个月死亡率较高。低危和中危组出院后的死亡率与高危患者相似。
{"title":"Fibrinolysis and clinical outcomes in acute pulmonary embolism. Madras medical college pulmonary embolism (M-PER) registry from India","authors":"","doi":"10.1016/j.ihj.2024.06.008","DOIUrl":"10.1016/j.ihj.2024.06.008","url":null,"abstract":"<div><h3>Background</h3><p>Acute pulmonary embolism (APE) is the third most common cause of vascular death. Data on APE from India and other low-and middle-income countries is sparse.</p></div><div><h3>Objectives</h3><p>Study the clinical characteristics, prognostic factors, in-hospital mortality (IMH) and 12 months mortality of patients with APE in India.</p></div><div><h3>Methods</h3><p>We prospectively enrolled 186 consecutive patients diagnosed with APE between November 2016 and November 2021 in Madras Medical College Pulmonary Embolism Registry (M-PER). All patients had electrocardiography and echocardiography. High risk patients and selected intermediate risk patients underwent fibrinolysis.</p></div><div><h3>Results</h3><p>75 % of our patients were below 50 years of age. 35 % were women. The mean time to presentation from symptom onset was 6.04 ± 10.01 days. 92 % had CT pulmonary angiography. Intermediate risk category (61.3 %) was the more common presentation followed by high risk (26.9 %). Electrocardiography showed S1Q3T3 pattern in 56 %. 76 % had right ventricular dysfunction and 12.4 % had right heart thrombi(RHT) by echocardiography. 50.5 % received fibrinolysis. Patients with RHT received fibrinolysis more frequently (78.3 % vs 46.6 %; <em>p</em> = 0.007). In-hospital mortality (IHM) was 15.6 %. Systemic arterial desaturation and need for mechanical ventilation independently predicted IHM. Ten patients (5.3 %) were lost to follow up. One year mortality was 26.7 % (47/176). One year mortality of patients discharged alive was similar among high, intermediate and low risk groups(14.8 % vs 1.9 % vs 10.5 %; <em>p</em> = 0.891).</p></div><div><h3>Conclusions</h3><p>Patients with PE are often young and present late in India. The in-hospital and 12 months mortality were high. Low and intermediate risk groups had a high post discharge mortality similar to high risk patients.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 172-181"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000816/pdfft?md5=9271347d815e3c7376e6f40a9c133cb4&pid=1-s2.0-S0019483224000816-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of atrial fibrillation on a 24-hour Holter in adult Indians 印度成年人 24 小时心电图中心房颤动的患病率。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.012

Objective

To evaluate paroxysmal atrial fibrillation (AF) prevalence in Indian adults who completed 24-Hour Holter monitoring.

Methods

A total of 23,847 patients (36.9 % women) were analyzed for AF duration using a software algorithm.

Results

AF was diagnosed in 4153 (17.4 %) patients with a median AF duration of 13 min and 55 s.

Conclusion

AF prevalence was high and largely untreated. The short duration of AF episodes indicates a low likelihood of detection during clinical visits, highlighting its potential underestimation in Indian healthcare.

目的评估完成 24 小时 Holter 监测的印度成年人中阵发性心房颤动(房颤)的发生率:使用软件算法对 23,847 名患者(36.9% 为女性)的房颤持续时间进行分析:结果:4153 名患者(17.4%)被诊断为房颤,中位房颤持续时间为 13 分 55 秒:结论:心房颤动发病率很高,且大多未得到治疗。心房颤动发作持续时间短,表明在临床就诊时被发现的可能性较低,这凸显了印度医疗机构可能低估了心房颤动的发病率。
{"title":"Prevalence of atrial fibrillation on a 24-hour Holter in adult Indians","authors":"","doi":"10.1016/j.ihj.2024.06.012","DOIUrl":"10.1016/j.ihj.2024.06.012","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate paroxysmal atrial fibrillation (AF) prevalence <strong>in Indian adults who completed 24-Hour Holter monitoring.</strong></p></div><div><h3>Methods</h3><p>A total of 23,847 patients (36.9 % women) were analyzed for AF duration using a software algorithm.</p></div><div><h3>Results</h3><p>AF was diagnosed in 4153 (17.4 %) patients with a median AF duration of 13 min and 55 s.</p></div><div><h3>Conclusion</h3><p>AF prevalence was high and largely untreated. The short duration of AF episodes indicates a low likelihood of detection during clinical visits, highlighting its potential underestimation in Indian healthcare.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 218-220"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000853/pdfft?md5=089ea16496c1eeed636b0ced7957883b&pid=1-s2.0-S0019483224000853-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart failure, the global pandemic: A call to action consensus statement from the global presidential conclave at the platinum jubilee conference of cardiological society of India 2023 心力衰竭,全球流行病:2023 年印度心脏病学会白金庆典大会全球主席会议共识声明。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.04.004

Heart failure (HF) is emerging as a major public health problem both in high- and low - income countries. The mortality and morbidity due to HF is substantially higher in low-middle income countries (LMICs). Accessibility, availability and affordability issues affect the guideline directed therapy implementation in HF care in those countries. This call to action urges all those concerned to initiate preventive strategies as early as possible, so that we can reduce HF-related morbidity and mortality. The most important step is to have better prevention and treatment strategies for diseases such as hypertension, ischemic heart disease (IHD), type-2 diabetes, and rheumatic heart disease (RHD) which predispose to the development of HF. Setting up dedicated HF-clinics manned by HF Nurses, can help in streamlining HF care. Subsidized in-patient care, financial assistance for device therapy, use of generic medicines (including polypill strategy) will be helpful, along with the use of digital technologies.

心力衰竭(HF)正在成为高收入和低收入国家的一个主要公共卫生问题。在中低收入国家,心力衰竭导致的死亡率和发病率要高得多。在这些国家,可及性、可用性和可负担性问题影响着高血压治疗指南的实施。这一行动呼吁敦促所有相关人员尽早启动预防策略,从而降低与心房颤动相关的发病率和死亡率。最重要的一步是针对高血压、缺血性心脏病(IHD)、2 型糖尿病和风湿性心脏病(RHD)等容易诱发心房颤动的疾病制定更好的预防和治疗策略。设立专门的心房颤动诊所,由心房颤动护士负责,有助于简化心房颤动护理。住院治疗补贴、器械治疗资助、非专利药品的使用(包括多药策略)以及数字技术的使用都将有所帮助。
{"title":"Heart failure, the global pandemic: A call to action consensus statement from the global presidential conclave at the platinum jubilee conference of cardiological society of India 2023","authors":"","doi":"10.1016/j.ihj.2024.04.004","DOIUrl":"10.1016/j.ihj.2024.04.004","url":null,"abstract":"<div><p>Heart failure (HF) is emerging as a major public health problem both in high- and low - income countries. The mortality and morbidity due to HF is substantially higher in low-middle income countries (LMICs). Accessibility, availability and affordability issues affect the guideline directed therapy implementation in HF care in those countries. This call to action urges all those concerned to initiate preventive strategies as early as possible, so that we can reduce HF-related morbidity and mortality. The most important step is to have better prevention and treatment strategies for diseases such as hypertension, ischemic heart disease (IHD), type-2 diabetes, and rheumatic heart disease (RHD) which predispose to the development of HF. Setting up dedicated HF-clinics manned by HF Nurses, can help in streamlining HF care. Subsidized in-patient care, financial assistance for device therapy, use of generic medicines (including polypill strategy) will be helpful, along with the use of digital technologies.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 147-153"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000579/pdfft?md5=21a02c9842145731941b3f3129ec1880&pid=1-s2.0-S0019483224000579-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of capacity building and tele ECG based decision support on change in thrombolysis rate and inhospital and one year mortality in patients with STEMI, using hub and spoke model; multi-phasic intervention trial 能力建设和基于远程心电图的决策支持对 STEMI 患者溶栓率、住院和一年死亡率变化的影响,采用中心辐射模式;多相干预试验。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.005

Background

We report the impact of capacity building and teleconsultation on change in the thrombolysis rates and one-year mortality in patients with STEMI using a hub and the spoke model of STEMI care.

Methods

Twenty secondary care public hospitals were linked with a teaching hospital as a hub centre and the impact of the intervention on change in ischemic time, thrombolysis rates and all-cause in-hospital and one-year mortality was compared.

Results

29 patients with STEMI were treated during pre-intervention from April 2020 to June 2020 and 255 patients during the post-intervention period from July 2020 to Oct 2021 in spoke centres. 245 patients were reported to a hub centre during the study period. The thrombolysis rate was significantly higher in the spoke centres after intervention (65.5%vs. 27.5 % p < 0.001) and was also significantly higher than in patients treated in a hub centre (65.5 % vs. 45.7 % p < 0.01). The in-hospital mortality was significantly lower in patients treated at spoke centres compared to those treated at the hub centre (7.8 % vs. 15.5 % < 0.003). The significant difference in mortality rate continued at one year (11.0 % vs.18.4 % p < 0.01). The median time from symptoms to thrombolytic therapy was significantly lower in STEMI patients treated in spoke centres compared to a hub centre (230 min vs. 356 min p < 0.001).

Conclusion

The hub and spoke model of STEMI care is effective in increasing thrombolysis rate, and decreasing in-hospital and one-year mortality rate.

背景我们报告了能力建设和远程会诊对 STEMI 患者溶栓率和一年死亡率变化的影响,采用的是 STEMI 护理的 "中心-轮辐 "模式。结果干预前(2020 年 4 月至 2020 年 6 月)有 29 名 STEMI 患者在辐式中心接受治疗,干预后(2020 年 7 月至 2021 年 10 月)有 255 名患者在辐式中心接受治疗。在研究期间,有 245 名患者向中心报告。干预后,轮辐中心的溶栓率明显较高(65.5% vs. 27.5 % p < 0.001),也明显高于在枢纽中心接受治疗的患者(65.5% vs. 45.7 % p < 0.01)。在辐射中心接受治疗的患者的院内死亡率明显低于在中心接受治疗的患者(7.8% vs. 15.5% <0.003)。一年后,死亡率仍有明显差异(11.0% 对 18.4% p <0.01)。与枢纽中心相比,在辐条中心接受治疗的 STEMI 患者从出现症状到接受溶栓治疗的中位时间明显缩短(230 分钟 vs. 356 分钟 p < 0.001)。
{"title":"Impact of capacity building and tele ECG based decision support on change in thrombolysis rate and inhospital and one year mortality in patients with STEMI, using hub and spoke model; multi-phasic intervention trial","authors":"","doi":"10.1016/j.ihj.2024.06.005","DOIUrl":"10.1016/j.ihj.2024.06.005","url":null,"abstract":"<div><h3>Background</h3><p>We report the impact of capacity building and teleconsultation on change in the thrombolysis rates and one-year mortality in patients with STEMI using a hub and the spoke model of STEMI care.</p></div><div><h3>Methods</h3><p>Twenty secondary care public hospitals were linked with a teaching hospital as a hub centre and the impact of the intervention on change in ischemic time, thrombolysis rates and all-cause in-hospital and one-year mortality was compared.</p></div><div><h3>Results</h3><p>29 patients with STEMI were treated during pre-intervention from April 2020 to June 2020 and 255 patients during the post-intervention period from July 2020 to Oct 2021 in spoke centres. 245 patients were reported to a hub centre during the study period. The thrombolysis rate was significantly higher in the spoke centres after intervention (65.5%vs. 27.5 % <em>p</em> &lt; 0.001) and was also significantly higher than in patients treated in a hub centre (65.5 % vs. 45.7 % <em>p</em> &lt; 0.01). The in-hospital mortality was significantly lower in patients treated at spoke centres compared to those treated at the hub centre (7.8 % vs. 15.5 % &lt; 0.003). The significant difference in mortality rate continued at one year (11.0 % vs.18.4 % <em>p</em> &lt; 0.01). The median time from symptoms to thrombolytic therapy was significantly lower in STEMI patients treated in spoke centres compared to a hub centre (230 min vs. 356 min <em>p</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>The hub and spoke model of STEMI care is effective in increasing thrombolysis rate, and decreasing in-hospital and one-year mortality rate.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 167-171"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000786/pdfft?md5=b9a05afaa1127f87d1be9229d5afe7e2&pid=1-s2.0-S0019483224000786-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141413369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical study 新型 FDC 替米沙坦+比索洛尔与对比替米沙坦+琥珀酸美托洛尔 ER 联合疗法治疗 1 期和 2 期高血压的疗效、安全性和耐受性比较:双盲、多中心、III 期临床研究。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.002

Aim

The present study compared the safety, efficacy, and tolerability of the new fixed-dose combination (FDC) of telmisartan 40 mg + bisoprolol 5 mg (TBP) tablets with the existing comparator FDC telmisartan 40 mg + metoprolol succinate ER 50 mg (TMS) tablets in patients with stage 1 and stage 2 hypertension.

Methodology

The multicentric, double-blind, parallel-group, comparative, prospective, phase-III clinical study involved 264 subjects with stage 1 and stage 2 hypertension from 10 centres across India. The selected subjects were randomized into two groups: group A received the TMS and group B received the new FDC TBP. The primary endpoint was the mean change in seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) from baseline to week 12 in both the control and study arms. The secondary endpoint was achieving the target of SeSBP <140 mmHg and SeDBP <90 mmHg from baseline to week 12 in both groups. Safety and tolerability parameters were evaluated in both groups based on adverse effects (AEs) reported by the patients and the physician.

Results

Both treatment groups exhibited a reduction in BP after 2 weeks of treatment, which was sustained until 12 weeks. The mean change in SeSBP and SeDBP at weeks 2, 6, and 12 compared to the previous visit showed statistical significance (p < 0.001) in all cases for both groups A and B. The mean changes in SeSBP and SeDBP from baseline to study end were numerically higher in group B than in group A. The mean difference in SeSBP from baseline to study end was significantly higher in group B compared to group A (p = 0.029). By week 12, 88.28 % and 89.84 % of subjects in group B achieved SeSBP <140 mmHg and SeDBP <90 mmHg respectively, while 86.71 % and 91.40 % of subjects in group A achieved the same targets. Reported AEs were mostly mild to moderate in both treatment groups, and no serious AEs or deaths were reported. Tolerability was rated as ‘excellent’ by 93.75 % of subjects in group B and 91.40 % of subjects in group A.

Conclusion

Both the new FDC TBP and the existing comparator TMS combination therapy have comparable efficacy, tolerability, and safety for the management of stage 1 and stage 2 hypertension.

Trial registry name

Clinical Trials Registry of India (CTRI)

Trial registration no

CTRI/2021/11/037,926

Protocol no

MLBTL/05/2021

Protocol url

https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=62069&EncHid=&userName=bisoprolol

目的:本研究比较了新型固定剂量复方制剂(FDC)替米沙坦40毫克+比索洛尔5毫克(TBP)片剂与现有的比较药固定剂量复方制剂替米沙坦40毫克+琥珀酸美托洛尔ER50毫克(TMS)片剂在1期和2期高血压患者中的安全性、有效性和耐受性:这项多中心、双盲、平行组、比较性、前瞻性的 III 期临床研究涉及印度 10 个中心的 264 名 1 期和 2 期高血压患者。选定的受试者被随机分为两组:A 组接受 TMS,B 组接受新型 FDC TBP。主要终点是对照组和研究组的坐位收缩压(SeSBP)和坐位舒张压(SeDBP)从基线到第 12 周的平均变化。次要终点是达到 SeSBP 结果的目标:治疗 2 周后,两组患者的血压均有所下降,并持续到 12 周。第 2、6 和 12 周的 SeSBP 和 SeDBP 平均值变化与前次访视相比具有统计学意义(P 结论:第 2、6 和 12 周的 SeSBP 和 SeDBP 平均值变化与前次访视相比具有统计学意义(P 结论):新的 FDC TBP 和现有的参照物 TMS 联合疗法在治疗 1 期和 2 期高血压方面具有相似的疗效、耐受性和安全性。试验登记处名称:印度临床试验登记处(CTRI),试验登记号:CTRI/2021/11/037926 PROTOCOL NO:MLBTL/05/2021 PROTOCOL URL:https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=62069&EncHid=&userName=bisoprolol。
{"title":"Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical study","authors":"","doi":"10.1016/j.ihj.2024.06.002","DOIUrl":"10.1016/j.ihj.2024.06.002","url":null,"abstract":"<div><h3>Aim</h3><p>The present study compared the safety, efficacy, and tolerability of the new fixed-dose combination (FDC) of telmisartan 40 mg + bisoprolol 5 mg (TBP) tablets with the existing comparator FDC telmisartan 40 mg + metoprolol succinate ER 50 mg (TMS) tablets in patients with stage 1 and stage 2 hypertension.</p></div><div><h3>Methodology</h3><p>The multicentric, double-blind, parallel-group, comparative, prospective, phase-III clinical study involved 264 subjects with stage 1 and stage 2 hypertension from 10 centres across India. The selected subjects were randomized into two groups: group A received the TMS and group B received the new FDC TBP. The primary endpoint was the mean change in seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) from baseline to week 12 in both the control and study arms. The secondary endpoint was achieving the target of SeSBP &lt;140 mmHg and SeDBP &lt;90 mmHg from baseline to week 12 in both groups. Safety and tolerability parameters were evaluated in both groups based on adverse effects (AEs) reported by the patients and the physician.</p></div><div><h3>Results</h3><p>Both treatment groups exhibited a reduction in BP after 2 weeks of treatment, which was sustained until 12 weeks. The mean change in SeSBP and SeDBP at weeks 2, 6, and 12 compared to the previous visit showed statistical significance (<em>p</em> &lt; 0.001) in all cases for both groups A and B. The mean changes in SeSBP and SeDBP from baseline to study end were numerically higher in group B than in group A. The mean difference in SeSBP from baseline to study end was significantly higher in group B compared to group A (<em>p</em> = 0.029). By week 12, 88.28 % and 89.84 % of subjects in group B achieved SeSBP &lt;140 mmHg and SeDBP &lt;90 mmHg respectively, while 86.71 % and 91.40 % of subjects in group A achieved the same targets. Reported AEs were mostly mild to moderate in both treatment groups, and no serious AEs or deaths were reported. Tolerability was rated as ‘excellent’ by 93.75 % of subjects in group B and 91.40 % of subjects in group A.</p></div><div><h3>Conclusion</h3><p>Both the new FDC TBP and the existing comparator TMS combination therapy have comparable efficacy, tolerability, and safety for the management of stage 1 and stage 2 hypertension.</p></div><div><h3>Trial registry name</h3><p>Clinical Trials Registry of India (CTRI)</p></div><div><h3>Trial registration no</h3><p>CTRI/2021/11/037,926</p></div><div><h3>Protocol no</h3><p>MLBTL/05/2021</p></div><div><h3>Protocol url</h3><p><span><span>https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=62069&amp;EncHid=&amp;userName=bisoprolol</span><svg><path></path></svg></span></p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 159-166"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000750/pdfft?md5=ec2c77a9c028415128a47dbccdef593b&pid=1-s2.0-S0019483224000750-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of three-dimensional (3-D) left ventricular ejection fraction and speckled tracking echocardiographic strain parameters in non-ischemic left bundle branch block (LBBB) patients and their association with cardiovascular events – A prospective observational study 评估非缺血性左束支传导阻滞(LBBB)患者的三维(3-D)左室射血分数和斑点追踪超声心动图应变参数及其与心血管事件的关系--一项前瞻性观察研究。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.011

Objective

To investigate the association between three-dimensional (3-D) left ventricular ejection fraction (LVEF) and various speckle tracking echocardiographic (STE) strain parameters in non-ischemic left bundle branch block (LBBB) patients with major adverse cardiovascular events (MACE) during a one-year follow-up phase.

Method

A total of 50 patients with non-ischemic LBBB were assessed using various parameters of 3-D echocardiography. They were compared with their same-age and sex control group and then followed up with repeat 3-D echocardiography for MACE for one year.

Results

Composite outcomes were seen in (n = 11 [22 %], including cardiovascular mortality (n = 2 [4.0 %]) and hospitalization for heart failure (n = 9 [18.0 %]). Mean values of the left ventricle (LV) global longitudinal (GLS), circumferential (GCS), and radial (GRS) strains were −14.4 ± 5.6, −14.3 ± 5.8, and 15.3 ± 5.9 respectively in the study cases. Initial GLS values were significantly impaired among those who had clinical events (−9.2 vs −15.9). Also, significant worsening of GLS (p value < 0.001) was seen in patients with composite outcomes on follow-up. Cut-off values in receiver operating characteristic analyses for composite outcomes were: GLS more than −13.5, GCS more than −12.5, and GRS less than 14.5. Intra-class correlations for both intra-observer and inter-observer variability were found to be good.

Conclusion

Impaired LV GLS and low 3-D LVEF are significantly associated with the occurrence of MACE in patients with non-ischemic LBBB. This strong association of LV GLS with outcomes can aid in risk stratification, prognostication, and clinical decision-making in non-ischemic LBBB.

目的研究随访一年的非缺血性左束支传导阻滞(LBBB)患者的三维(3-D)左室射血分数(LVEF)与各种斑点追踪超声心动图(STE)应变参数之间的关系:使用三维超声心动图的各种参数对50名非缺血性左束支传导阻滞患者进行评估。将他们与同年龄、同性别的对照组进行比较,然后通过重复三维超声心动图检查随访一年,以了解 MACE:结果:11 例患者出现了综合结果,包括心血管死亡(2 例[4.0%])和心力衰竭住院(9 例[18.0%])。研究病例的左心室整体纵向应变(GLS)、周向应变(GCS)和径向应变(GRS)的平均值分别为-14.4 ± 5.6、-14.3 ± 5.8和15.3 ± 5.9。在发生临床事件的病例中,初始 GLS 值明显受损(-9.2 vs -15.9)。此外,在随访期间出现综合结果的患者中,GLS 也明显恶化(P 值小于 0.001)。在接收器操作特征分析中,综合结果的临界值为GLS大于-13.5,GCS大于-12.5,GRS小于14.5。观察者内和观察者间变异性的类内相关性良好:结论:左心室GLS受损和低3-D LVEF与非缺血性LBBB患者MACE的发生密切相关。LV GLS与预后的密切关系有助于非缺血性LBBB患者的风险分层、预后和临床决策。
{"title":"Assessment of three-dimensional (3-D) left ventricular ejection fraction and speckled tracking echocardiographic strain parameters in non-ischemic left bundle branch block (LBBB) patients and their association with cardiovascular events – A prospective observational study","authors":"","doi":"10.1016/j.ihj.2024.06.011","DOIUrl":"10.1016/j.ihj.2024.06.011","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the association between three-dimensional (3-D) left ventricular ejection fraction (LVEF) and various speckle tracking echocardiographic (STE) strain parameters in non-ischemic left bundle branch block (LBBB) patients with major adverse cardiovascular events (MACE) during a one-year follow-up phase.</p></div><div><h3>Method</h3><p>A total of 50 patients with non-ischemic LBBB were assessed using various parameters of 3-D echocardiography. They were compared with their same-age and sex control group and then followed up with repeat 3-D echocardiography for MACE for one year.</p></div><div><h3>Results</h3><p>Composite outcomes were seen in (<em>n</em> = 11 [22 %], including cardiovascular mortality (<em>n</em> = 2 [4.0 %]) and hospitalization for heart failure (<em>n</em> = 9 [18.0 %]). Mean values of the left ventricle (LV) global longitudinal (GLS), circumferential (GCS), and radial (GRS) strains were −14.4 ± 5.6, −14.3 ± 5.8, and 15.3 ± 5.9 respectively in the study cases. Initial GLS values were significantly impaired among those who had clinical events (−9.2 vs −15.9). Also, significant worsening of GLS (<em>p</em> value &lt; 0.001) was seen in patients with composite outcomes on follow-up. Cut-off values in receiver operating characteristic analyses for composite outcomes were: GLS more than −13.5, GCS more than −12.5, and GRS less than 14.5<strong>.</strong> Intra-class correlations for both intra-observer and inter-observer variability were found to be good.</p></div><div><h3>Conclusion</h3><p>Impaired LV GLS and low 3-D LVEF are significantly associated with the occurrence of MACE in patients with non-ischemic LBBB. This strong association of LV GLS with outcomes can aid in risk stratification, prognostication, and clinical decision-making in non-ischemic LBBB.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 210-217"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000841/pdfft?md5=0be4f749fc53b6cef525e35bd22b9058&pid=1-s2.0-S0019483224000841-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of residual SYNTAX score in patients with coronary artery disease undergoing percutaneous coronary intervention-cohort study 接受经皮冠状动脉介入治疗的冠心病患者残余 SYNTAX 评分的预后价值--队列研究。
IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-05-01 DOI: 10.1016/j.ihj.2024.06.006

Residual Syntax Score (RSS) is derived from Syntax Score to quantify the burden of residual coronary artery disease after percutaneous coronary intervention (PCI). As data is limited, we report predictive utility of Residual SYNTAX Score in relation to in hospital and 1 year mortality of the patients undergoing percutaneous coronary intervention (PCI).

残余语法评分(RSS)源自语法评分,用于量化经皮冠状动脉介入治疗(PCI)后残余冠状动脉疾病的负担。由于数据有限,我们报告了残余SYNTAX评分对接受经皮冠状动脉介入治疗(PCI)患者的住院死亡率和1年死亡率的预测作用。
{"title":"Prognostic value of residual SYNTAX score in patients with coronary artery disease undergoing percutaneous coronary intervention-cohort study","authors":"","doi":"10.1016/j.ihj.2024.06.006","DOIUrl":"10.1016/j.ihj.2024.06.006","url":null,"abstract":"<div><p>Residual Syntax Score (RSS) is derived from Syntax Score to quantify the burden of residual coronary artery disease after percutaneous coronary intervention (PCI). As data is limited, we report predictive utility of Residual SYNTAX Score in relation to in hospital and 1 year mortality of the patients undergoing percutaneous coronary intervention (PCI).</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 3","pages":"Pages 221-223"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483224000798/pdfft?md5=03d5cc0a5062dd9db955fd16215b672a&pid=1-s2.0-S0019483224000798-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian heart journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1